ProfileGDS4814 / ILMN_1872276
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 53% 58% 60% 62% 59% 58% 53% 34% 63% 60% 63% 60% 57% 55% 53% 51% 48% 50% 63% 56% 51% 60% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)51.536953
GSM780708Untreated after 4 days (C2_1)53.748858
GSM780709Untreated after 4 days (C3_1)55.207460
GSM780719Untreated after 4 days (C1_2)57.42562
GSM780720Untreated after 4 days (C2_2)54.414259
GSM780721Untreated after 4 days (C3_2)54.111558
GSM780710Trastuzumab treated after 4 days (T1_1)51.795553
GSM780711Trastuzumab treated after 4 days (T2_1)46.410134
GSM780712Trastuzumab treated after 4 days (T3_1)58.597363
GSM780722Trastuzumab treated after 4 days (T1_2)55.520260
GSM780723Trastuzumab treated after 4 days (T2_2)58.406163
GSM780724Trastuzumab treated after 4 days (T3_2)55.114960
GSM780713Pertuzumab treated after 4 days (P1_1)53.450157
GSM780714Pertuzumab treated after 4 days (P2_1)52.313155
GSM780715Pertuzumab treated after 4 days (P3_1)51.453153
GSM780725Pertuzumab treated after 4 days (P1_2)51.001651
GSM780726Pertuzumab treated after 4 days (P2_2)49.91748
GSM780727Pertuzumab treated after 4 days (P3_2)50.670550
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)58.126463
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)52.915856
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)50.96251
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)55.752960
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)56.800462